266 related articles for article (PubMed ID: 1377002)
21. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
[TBL] [Abstract][Full Text] [Related]
23. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.
Tornesello ML; Buonaguro L; Buonaguro FM
Gynecol Oncol; 2013 Mar; 128(3):442-8. PubMed ID: 23168175
[TBL] [Abstract][Full Text] [Related]
24. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene.
Cerutti P; Hussain P; Pourzand C; Aguilar F
Cancer Res; 1994 Apr; 54(7 Suppl):1934s-1938s. PubMed ID: 7907948
[TBL] [Abstract][Full Text] [Related]
25. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
27. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran.
Sepehr A; Tanière P; Martel-Planche G; Zia'ee AA; Rastgar-Jazii F; Yazdanbod M; Etemad-Moghadam G; Kamangar F; Saidi F; Hainaut P
Oncogene; 2001 Nov; 20(50):7368-74. PubMed ID: 11704866
[TBL] [Abstract][Full Text] [Related]
28. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides.
Soussi T; Béroud C
Hum Mutat; 2003 Mar; 21(3):192-200. PubMed ID: 12619105
[TBL] [Abstract][Full Text] [Related]
29. p53 alterations in plutonium-induced F344 rat lung tumors.
Kelly G; Stegelmeier BL; Hahn FF
Radiat Res; 1995 Jun; 142(3):263-9. PubMed ID: 7761575
[TBL] [Abstract][Full Text] [Related]
30. Codon 249 of the human TP53 tumor suppressor gene is no hot spot for aflatoxin B1 in a heterologous background.
Sengstag C; Mörbe JL; Weibel B
Mutat Res; 1999 Nov; 430(1):131-44. PubMed ID: 10592324
[TBL] [Abstract][Full Text] [Related]
31. Somatic TP53 Mutations in the Era of Genome Sequencing.
Hainaut P; Pfeifer GP
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27503997
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutations in primary lung tumors are conserved in brain metastases.
Schlegel U; Rosenfeld MR; Volkenandt M; Rosenblum M; Dalmau J; Furneaux H
J Neurooncol; 1992 Oct; 14(2):93-100. PubMed ID: 1331352
[TBL] [Abstract][Full Text] [Related]
33. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
34. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
36. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
37. Mutational spectra of human cancer.
Pfeifer GP; Besaratinia A
Hum Genet; 2009 Jun; 125(5-6):493-506. PubMed ID: 19308457
[TBL] [Abstract][Full Text] [Related]
38. TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression.
Faria MH; Neves Filho EH; Alves MK; Burbano RM; de Moraes Filho MO; Rabenhorst SH
APMIS; 2012 Nov; 120(11):882-9. PubMed ID: 23009112
[TBL] [Abstract][Full Text] [Related]
39. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
40. Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP.
Srividya ; Giridhar BH; Vishwanath S; Chakraborty A
Pathol Oncol Res; 2019 Oct; 25(4):1373-1377. PubMed ID: 29500733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
